Kornimate/medical-research-clean huggingface dataset:
hybrid model of vocal inflammation and tissue mobilization

Conditions: Acute Phonotrauma

Summary: the purpose of this study is to generate a technology that will allow clinicians to prescribe behavioral treatment that should optimize tissue healing for both acute and chronic phonotrauma. in this study, we propose to (1): establish a non-invasive methodology for estimating overall mechanical dose during phonation, and component metrics of phonatory mechanical dose (e.g., distance dose, energy dissipation dose and time dose) from high speed imaging data and aeromechanical modeling, for a range of vocal fold configurations (experiment 1); (2): identify mathematical relations between treatment dose parameters, inflammatory state of the tissue and time-varying biological consequences in the tissue, up to 2 wk following acute phonotrauma (experiment 2); (3): develop a hybrid physical-biological model of vocal fold inflammation and treatment to identify treatment modalities that should optimize post-traumatic wound healing at 2 wk, for a range of acute phonotraumatic conditions (experiment 3-no human subject involved), and (4): provide a preliminary test of the hybrid treatment models' ability to predict idealized treatment outcome in human subjects, and calibrate the model as needed iteratively to achieve a match between predicted and obtained outcomes (experiment 4).


Eligibility criteria:
inclusion criteria: * healthy females * ages 18-40 * generally healthy * normal hearing bilaterally at 20 db to 8,000 hz * have ability to produce "resonant voice" during training as determined by the examiner perceptually * tolerate rigid and nasal endoscopy without anesthesia to the larynx nasal patency allowing for the passage of an endoscope unilaterally exclusion criteria: * smoking within the past five yr * failing a hearing screening test * having current chronic voice problems * having current medications that are determined to possibly influence voice * having heightened gag reflex * having known or suspected allergy to anesthetics * pregnancy reported

Keywords: acute phonotrauma computer modeling resonant voice breathy voice voice rest relaxation
heart rate variability and diabetic kidney disease in type 2 diabetes mellitus patients

Conditions: Type2 Diabetes Mellitus

Summary: several studies have investigated an association between cardiac autonomic neuropathy (can) and albuminuria, glomerular filtration rate, or both, and hypothesized that can is involved in the pathogenesis of nephropathy. however, most of these studies had focused on caucasians and were limited to a small number of patients with type 1 diabetes mellitus, or had used a conventional ewing battery of tests based on dynamic cardiovascular maneuvers.yet, there is consistent data showing that asian diabetic populations, including the chinese, have a higher risk of renal complications than caucasians do. the present study investigated an association between heart rate variability (hrv) parameters and diabetic kidney disease (dkd) in chinese type 2 diabetes mellitus (t2dm) patients, specifically through time and frequency domain analyses of hrv and urine albumin creatinine ratio (uacr) or estimated glomerular filtration rate (egfr).

present study investigated an association between hrv parameters and dkd in chinese t2dm patients, specifically through time and frequency domain analyses of hrv and uacr or egfr

Eligibility criteria:
inclusion criteria: * clinical diagnosis of t2dm * adult patients has had consecutively undergone 24-hour holter monitoring for heart rate variability analysis exclusion criteria: * patients with acute complications of dm including diabetic ketoacidosis, hyperosmolar coma * foot ulcer * severe acute or chronic infection * chronic liver disease * dialysis or renal transplantation * the presence of any serious concomitant disease affecting life expectancy were not eligible for the study.
evaluation of diprospan injection to the knee on rehabilitation of patients after tkr of the contralateral knee

Conditions: Osteoarthritis

Summary: this study is performed to assess the influence of intraarticular injection of 2ml diprospan (wich contains 4mg betamethasone sodium phosphate and 10mg betamethasone dipropionate) into osteoarthritic knee in patients who undergo a total knee replacement of their contralateral knee. the study population will include 50 patients with bilateral knee osteoarthritis, admitted for their first knee replacement surgery. only patients with older than 50 years with primary osteoarthritis will be included. the patients will be randomized into 2 groups. intervention group will receive an injection of 2ml diprospan diluted in 10 ml bupivocaine. the control group will receive an injection of 10ml of bupivocaine. all patients will be followed after 6 weeks and three functional rehabilitation and pain scores will be assessed (vas pain score, timed up and go score and functional ambulatory category scale).


Eligibility criteria:
inclusion criteria: * age older than 50 * bilateral primary knee osteoarthritis * undergoing knee arthroplasty exclusion criteria: * active infection * allergy to medication compounds * pregnancy

Keywords: osteoarthritis knee arthroplasty steroid injection rehabilitation
retrospective analyses of trakstar database

Conditions: Depression; Obsessive-Compulsive Disorder; Anxiety Depression

Summary: in this study, real-world data will be used to better understand the effects patient characteristics, symptoms and tms protocol parameters have on clinical outcomes with neurostar tms.


Eligibility criteria:
inclusion criteria: * male or female reported in database and not an invalid entry * age reported and not an invalid entry * treatment date of november 01, 2008 or later. exclusion criteria: • incomplete information on treatment parameters

Keywords: tms
randomized trial of follow-up strategies in breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to determine whether family physician 'routine follow-up care' of women with breast cancer in remission is an acceptable alternative to the existing system of specialist follow-up. primary outcome measure are event rates of oncological catastrophes and quality of life.

see above

Eligibility criteria:
inclusion criteria: * women with breast cancer on well follow-up at regional cancer centres in ontario and manitoba * diagnosed at least 12 months previously (range 9-15 months) * without evidence of active disease (i.e., stages iiib and iv excluded) * free from any primary treatment complications exclusion criteria: * primary treatment at least 3 months previously, except for continued use of tamoxifen * still experiencing complications of primary treatment (patients will become eligible once complications resolve provided they are within the 6 month window) * unable to identify an acceptable family physician to provide follow-up * language or literacy skills inconsistent with completing questionnaires * unable to comply with study protocol including completion of questionnaires * previously enrolled in a study which requires continued follow-up in specialist or peripheral clinics * actively followed at a cancer centre for another primary cancer

Keywords: breast cancer follow-up strategy follow-up care family physician oncologist
platelet rich fibrin in the treatment of full thickness palatal wounds

Conditions: Gingival Recession

Summary: in this study it will be investigated the usefulness of platelet-rich fibrin (prf) on in the full thickness palatal graft donor site healing acceleration and in the patient's morbidity reduction. eighty patients, with at least one gingival recession will be treated by a flap with connective tissue graft(ctg). in the test group (20 patients) and in the control group 2 a quadruple layer of prf membrane will be placed over the palatal wounds; conversely, the control groups 2-4 patients will be treated by an absorbable gelatin sponge. patients will be monitored at 1, 2, 3 and 4 weeks after surgery for the complete re-epithelialization of the palatal wound (cwe), the alteration of sensibility (as) around the wound area, the post-operative discomfort (d), and the changes of feeding habits (cfh) by a visual analogic scale (vas) evaluation. furthermore, the analgesics consumption and the existence of delayed bleeding from the palatal wound (dwb) during the first post-operative week will be assessed.

in this study it will be investigated the usefulness of platelet-rich fibrin (prf) on in the full thickness palatal graft donor site healing acceleration and in the patient's morbidity reduction. eighty patients, with at least one gingival recession will be treated by a coronally advanced flap (caf) with connective tissue graft(ctg) resulting from the de-epithelialization of a free gingival graft. in the test group (20 patients) a quadruple layer of prf membrane will be placed over the palatal wounds; conversely, the control groups patients will be treated by an absorbable gelatin sponge. patients will be monitored at 1, 2, 3 and 4 weeks after surgery for the complete re-epithelialization of the palatal wound (cwe), the alteration of sensibility (as) around the wound area, the post-operative discomfort (d), and the changes of feeding habits (cfh) by a visual analogic scale (vas) evaluation. furthermore, the analgesics consumption and the existence of delayed bleeding from the palatal wound (dwb) during the first post-operative week will be assessed.

Eligibility criteria:
inclusion criteria: * to have a single gingival recession to be treated by a mucogingival surgery intervention * to be in good systemic health * to have a good oral hygiene exclusion criteria: * no systemic diseases; no coagulation disorders; no medications affecting periodontal status in the previous 6 months; no pregnancy or lactation; * no smoking habits; * no periodontal surgery on the experimental sites; * no inadequate endodontic treatment * no tooth mobility at the site of surgery
risk assessment and treat compliance in hypertension education trial

Conditions: Hypertension; Dyslipidemia

Summary: the ratchet study assesses if patient knowledge of estimated cardiovascular risk at current and recommended target blood pressure levels improves compliance in the management of hypertension.


Eligibility criteria:
inclusion criteria: * essential hypertension (new diagnosis or established diagnosis) meeting criteria for pharmacologic therapy as defined by current guidelines exclusion criteria: * lack of written informed consent * previous myocardial infarction * previous stroke * congestive heart failure * stage 3 or greater chronic kidney disease * pregnancy * usage of medication bubble/blister package

Keywords: hypertension compliance
making memory better for seniors with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: the purpose of this study is to investigate the feasibility and effectiveness of a cognitive training group in individuals with mild cognitive impairment, using a new paradigm that will optimize ecological validity by (1) focusing on everyday memory problems, (2) supplementing traditional memory training with the teaching of an empirically-supported problem-solving approach, and (3) employing a clinically representative sample of individuals with mci (e.g., not excluding those with mild affective symptoms).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild cognitive impairment exclusion criteria: * clinical diagnosis of dementia * history of neurological conditions known to impair cognition * history of alcohol or drug abuse * history of chronic psychiatric illness * current symptoms of moderate to severe depression (geriatric depression scale \>19) or anxiety (beck anxiety inventory \>15)

Keywords: mild cognitive impairment aging memory executive function cognitive intervention memory training mental health
sleep disorder and oral habits in children

Conditions: Sleep Disorder; Malocclusion

Summary: sleep is a vital physiological function for the maintenance of health and quality of life. harmful, non-nutritive and parafunctional oral habits are believed to have a negative effect on adequate rest at night. the aim of the present study was to determine associations between quality of sleep and harmful oral habits among children aged three to six years. fifty children from a private school in são paulo (brazil) were evaluated using two questionnaires on sleep quality and harmful oral habits. the data were submitted to descriptive analysis. the chi-square test was employed for the categorical variables and analysis of variance (anova) was carried out to compare mean values. the student's t-test was used for all analyses, with the significance level set at 5%. the spss 12.0 program for windows was used to analyze the results.

an observational cross-sectional study was carried out with the aim of determining associations between quality of sleep and harmful oral habits among children aged three to six years. this study was conducted in compliance with the brazilian national health council/ministry of health guidelines contained in resolution 196/96 and received approval from the human research ethics committee of the universidade metropolitana de santos (brazil) under process number 026/2010. parents/guardians of all participants were properly informed regarding the objectives of the study and signed a statement of informed consent. fifty children (3 to 6 years of age) from a private school in the city of sao paulo were evaluated by means of two questionnaires administered to parents/guardians: the "undesirable habits questionnaire", composed of 15 investigative questions on harmful oral habits as well as dietary and psychological factors, and the sleep habits questionnaire.6 the data were submitted to descriptive analysis. the chi-square test was employed for the categorical variables and analysis of variance (anova) was carried out to compare mean values. the student's t-test was used for all analyses, with the significance level set at 5%. the spss 12.0 program for windows was used to analyze the results.

Eligibility criteria:
inclusion criteria: * 3 to 6 years of age exclusion criteria: * over 6 years of age

Keywords: sleep disorder malocclusion children
comparative efficacy & safety study of d961h versus placebo for the prevention of gastric and duodenal ulcers with low-dose aspirin

Conditions: Prevention

Summary: to assess the efficacy of d961h 20 mg once daily (q.d.) versus placebo in continuous treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily low-dose aspirin therapy by evaluating time from randomisation to occurrence of gastric and/or duodenal ulcers.


Eligibility criteria:
inclusion criteria: * provision of written informed consent before starting the study-related procedures and examinations * patients who have the history of gastric and/or duodenal ulcer. * a diagnosis of a chronic condition (angina pectoris, myocardial infarction and ischemic cerebrovascular disorder, etc., requiring prevention of thrombosis or embolism) which requires taking the prescribed lda during the study treatment period. exclusion criteria: * having gastric or duodenal ulcer (except for ulcer scar). * history of esophageal, gastric or duodenal surgery, except for simple closure of perforation.

Keywords: gastric ulcer duodenal ulcer low-dose aspirin
a study of mk-0616 in healthy adult participants (mk-0616-009)

Conditions: Hypercholesterolemia

Summary: the goal of the study is to learn what happens to levels of mk-0616 in the blood when mk-0616 is given in different forms. researchers believe that there is no effect on a healthy person's body if mk-0616 is given in different forms.


Eligibility criteria:
inclusion criteria: the key inclusion criteria include but are not limited to the following: * is in good health before randomization * has a body mass index (bmi) ≥18 and ≤32 kg/m\^2, inclusive exclusion criteria: the key exclusion criteria include but are not limited to the following: * has a history of clinically significant endocrine, gi, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases * has a history of cancer with pre-specified exceptions (adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies that have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study, per protocol guidelines)
study evaluating the safety and effectiveness in subjects with tigecycline treatment

Conditions: Complicated Skin and Skin Structure Infections; Complicated Intra-abdominal Infections; Community-Acquired Bacterial Pneumonia

Summary: the primary objective of this study is to identify any changes on the safety profile of adverse events and serious adverse events. and the secondary objective is to evaluate clinical response in the clinically evaluable population at test-of cure (toc) or at the end of treatment (eot) assessment, and microbiologic response at the subject level, if available.

prior to the conduct of this study, the investigator will explain the study objective, etc to prospective subjects on the basis of "explanatory material." the informed consent will be obtained in written form by each subject voluntarily.

Eligibility criteria:
inclusion criteria: evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study. subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study : adults 18 years of age or older, who have one of the followings: * complicated skin and skin structure infections * complicated intra-abdominal infections * community-acquired bacterial pneumonia exclusion criteria: subjects presenting with any of the following will not be included in the study: * patients who have known hypersensitivity to tigecycline * patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency, or glucose-galactose malabsorption

Keywords: infection tygacil pms
quantification of hepatic steatosis with different ultrasound frequency

Conditions: Fatty Liver; Fatty Liver, Nonalcoholic; Ultrasound

Summary: the objective of this study is: (1) to compare the feasibility (technical successes rate and reliability) in measuring attenuation coefficient between two different frequencies (3mhz, 4mhz) of ultrasound beam; (2) to evaluate and compare the diagnostic performance of attenuation coefficient for steatosis using two different frequencies (3mhz, 4mhz) of ultrasound beam by comparison with the pathologic results acquired by liver biopsy or surgery.

investigators measure the distance between the skin and liver capsule on b-mod images. investigators place a region of interest (roi) avoiding reverberation artifacts and acquire attenuation coefficient for five times. for participants who require a liver biopsy, investigators try to target the same area in the liver, where roi was placed. investigators evaluate hepatic steatosis, lobular inflammation, and fibrosis of tissue of the liver using a scoring system suggested by nonalcoholic steatohepatitis clinical research network.

Eligibility criteria:
inclusion criteria: * participants who are candidates for liver donation and scheduled liver biopsies for assessment of hepatic steatosis * participants suspected of nonalcoholic fatty liver disease and scheduled for liver biopsy or surgery exclusion criteria: * participants with a bmi of less than 23 * participants underwent liver transplantation or right hepatectomy * participants who have a large mass in the right liver * participants who have a bleeding tendency (platelet count \ 1.5)

Keywords: hepatic steatosis quantification ultrasound attenuation coefficient
efficacy study of zeller entspannung film coated tablets on acute stress

Conditions: The Primary Condition Studied for This Trial is Acute Stress

Summary: the objective of the stress trial is to investigate in a mode of action setting the effect of zeller entspannung film coated tablets on saliva cortisol response versus placebo after acute stress in healthy male volunteers. in addition, data on safety and tolerability of zeller entspannung will be obtained. a third arm including no treatment is tested as well. approximately 72 healthy volunteers will be included into this randomized, double blind study. study duration will be 7 days, study medication intake will be over 4 days: participants will take the medication one tablet three times a day (morning, midday, evening) the first 3 days, whereas on day 4 only two tablets will be taken (morning and midday).


Eligibility criteria:
inclusion criteria: * age:18 - 45 years * written informed consent * male gender exclusion criteria: * any acute or chronic somatic or psychiatric disorder * smoking * any clinically relevant hepatic disorder * any clinically relevant renal disorder * any clinically relevant cardiac disorder * any clinically relevant respiratory disease (e.g. asthma) * diabetes mellitus * any abnormal lab values suggesting diseases from exclusion criteria * known allergies to trial medication and excipients * alcohol or other drug abuse (e.g. cannabis) * concomitant participation in another clinical trial or \<4 weeks ago * participation in any psychotherapy * already participated in a tsst
early intervention with fluoxetine in autism

Conditions: Autistic Disorder

Summary: this study is a pilot study to evaluate the feasibility and safety of conducting a year long, double-blind, placebo-controlled trial of fluoxetine in pre-school children to enhance developmental processes in core areas impacted by autism.

autism, a brain disorder that affects a small percentage of americans, often results in a lifetime of impaired thinking, feeling, and social functioning. the disorder generally becomes apparent in children by the age of 3. autism typically affects a person's ability to communicate, form relationships with others, and respond appropriately to the external world. some people with autism can function at a relatively high level, with speech and intelligence intact. others have serious cognitive impairments and language delays, and some never speak. this study will assess the safety and effectiveness of treating autistic children with fluoxetine to enhance developmental processes in core areas impacted by autism. each participant was randomly assigned to treatment with double-blinded placebo or fluoxetine for 12 months. after initial screening and randomization, participants were assessed every two weeks for approximately the first 3 months, or until the dose of medication is stabilized. after this initial period, they were assessed on a monthly basis. dosing was flexible as determined by the adverse and beneficial responses to treatment although there was a suggested titration schedule.

Eligibility criteria:
inclusion criteria: * diagnosis of autism exclusion criteria: * diagnosis of asperger syndrome, rett syndrome, childhood disintegrative disorder, or pervasive development disorder-not otherwise specified * informed that treatment with a selective serotonin reuptake inhibitor (ssri) is medically inadvisable * need for ongoing psychotropic medication (except for diphenhydramine, clonidine, or melatonin for sleep) * recent use of stimulants within 5 days prior to enrollment * ongoing need for or recent use of most psychotropic medications within 14 days of enrollment * recent initiation of specialized educational, behavioral, or diet intervention for autism in the month prior to enrollment

Keywords: autism